Allergies, Volume 3, Issue 4 (December 2023) – 2 articles

Allergic rhinitis is the most common immune disorder worldwide, affecting approximately 10–40% of the general population. It is characterized by an inflammatory response of the nasal mucosa following exposure to non-infectious, inhaled, and airborne allergens that are defined based on the period of exposure to the allergen as annual, seasonal, or episodic. A variety of factors are found to relate to the prevalence of allergic rhinitis, i.e., sex, race, age, seasonality, personal and family-positive atopic history, as well as exposure to environmental and epigenetic factors. In addition to the local inflammation in the nasal mucosa, systemic inflammation is activated in the entire respiratory system, such as rhinoconjunctivitis, asthma, sinusitis, and otitis media with effusion. The aim of this study was to evaluate the trends in the prevalence of allergic rhinitis in the Greek pediatric and adolescent population since 1990. Research was performed in electronic databases (PubMed, ScienceDirect, and Cochrane Library) using appropriate MeSH terms for related studies from 1990 to 2023. We found 12 studies, 11 prospective and 1 cross-sectional, conducted in the cities of Athens, Thessaloniki, Patras and Evros prefecture, with sample sizes varying from 517 to 3076 subjects aged 6–17 years old. The prevalence of allergic rhinitis showed geographic and temporal variability, ranging between 2.1 and 32.5% in children and 25.3 and 30.8% in adolescents, with increasing trends. Factors such as gender (male), age (8–10 years), environmental exposures (moisture, mites, and fungi), positive atopic profile, and family history (asthma and eczema) were related to the manifestation of the disease. The need for systematic research in the Greek child and adolescent population is vital to recognize, prognosis, and control allergic rhinitis manifestations. Full article

Eriobotrya japonica (E. japonica) leaves have been used as an herbal traditional medicine in China and Japan owing to their anti-inflammatory and protective effects against skin conditions and allergy symptoms. These beneficial effects are likely mediated by the various triterpenoids present in E. japonica leaves. However, the efficacy of E. japonica leaves in the treatment of allergic rhinitis has not been evaluated in humans. Therefore, in the present study, a randomized, controlled, double-blind trial was performed on healthy adults of age >20 (n = 27) who were randomly assigned to receive either 2.5 g of placebo or E. japonica leaf supplements once daily for 4 weeks. The Japanese Allergic Rhinitis Quality of Life Standard Questionnaire (JRQLQ), dermatological allergy symptoms, Dermatology Life Quality Index, and skin condition parameters were assessed at baseline and after 4 weeks. Significant differences were observed in the variability of the itchy nose, itchy eyes, and eye symptoms between the E. japonica supplementation and placebo groups after 4 weeks. Arm skin transepidermal water loss was improved only in the E. japonica supplementation group. This study suggests that E. japonica leaves can be used as a functional food ingredient to relieve allergic symptoms. Full article